Don't take the jab

Was you on the fence about getting a vaccination?


  • Total voters
    102

zubenelgenubi

I'm a star
Again.. I did look at it. Apparently you did not. There are two bills here OK?

Infrastructure (that passed despite the far left not supporting it) and the AOC backed Socialism for All bill which King Joeseph is having a hard time getting his Congress to agree to thanks to opposition within his own party.

Believe me, I’m not a fan of socialism. I work for a living.

Don’t automatically base your response on who is in office.

I've had to help some people understand this. They don't realize there were two different bills. The one that passed had less spending than Trump was calling for.
 

AKCoverMan

Well-Known Member

Meanwhile: Pfizer reports 3Q results
  • Third-Quarter 2021 Revenues of $24.1 Billion, Reflecting 130% Operational Growth; Excluding Comirnaty(1), Revenues Grew 7% Operationally to $11.1 Billion
  • Third-Quarter 2021 Reported Diluted EPS(2) of $1.42, Adjusted Diluted EPS(3) of $1.34
  • Raises Full-Year 2021 Guidance(4) for Revenues to a Range of $81.0 to $82.0 Billion and Adjusted Diluted EPS(3) to a Range of $4.13 to $4.18, Reflecting 94% and 84% Year-Over-Year Growth at the Midpoints, Respectively
    • Anticipates 2021 Revenues of Approximately $36 Billion for Comirnaty(1), Reflecting 2.3 Billion Doses Expected to be Delivered in Fiscal 2021
    • Raises Midpoint of Guidance for Adjusted Diluted EPS(3) Excluding Comirnaty(1) to a Range of $2.60 to $2.65
  • Will Highlight Promising New Data on Multiple Novel Compounds in I&I, as Well as Clinical and Regulatory Updates for Gene Therapy and COVID-19 Development Programs on Conference Call
So I guess if I question the vax and interrupt the nonstop growth in revenue to your company I’m a criminal?
 

Meanwhile: Pfizer reports 3Q results
  • Third-Quarter 2021 Revenues of $24.1 Billion, Reflecting 130% Operational Growth; Excluding Comirnaty(1), Revenues Grew 7% Operationally to $11.1 Billion
  • Third-Quarter 2021 Reported Diluted EPS(2) of $1.42, Adjusted Diluted EPS(3) of $1.34
  • Raises Full-Year 2021 Guidance(4) for Revenues to a Range of $81.0 to $82.0 Billion and Adjusted Diluted EPS(3) to a Range of $4.13 to $4.18, Reflecting 94% and 84% Year-Over-Year Growth at the Midpoints, Respectively
    • Anticipates 2021 Revenues of Approximately $36 Billion for Comirnaty(1), Reflecting 2.3 Billion Doses Expected to be Delivered in Fiscal 2021
    • Raises Midpoint of Guidance for Adjusted Diluted EPS(3) Excluding Comirnaty(1) to a Range of $2.60 to $2.65
  • Will Highlight Promising New Data on Multiple Novel Compounds in I&I, as Well as Clinical and Regulatory Updates for Gene Therapy and COVID-19 Development Programs on Conference Call
So I guess if I question the vax and interrupt the nonstop growth in revenue to your company I’m a criminal?
Money is definitely leading this vaccination campaign
 
Top